ScienceDaily
Your source for the latest research news
Follow Facebook Twitter LinkedIn Subscribe RSS Feeds Newsletters
New:
  • Black Death Shaped Evolution of Immunity Genes
  • Methane-Eating 'Borgs' Taking Earth's Microbes
  • Pain Relief Without Side Effects and Addiction
  • Accounting For Dark Energy and Dark Matter
  • Meet the First Neanderthal Family
  • Physicists Confirm Hitch in Proton Structure
  • Five Hours' Sleep a Night: Disease Risk
  • Energetics of Piercing Fangs and Claws
  • Hair Straightening Chemicals and Uterine Cancer
  • Ostriches With Similar Interests Form Groups
advertisement
Follow all of ScienceDaily's latest research news and top science headlines!
Science News
from research organizations

1

2

Discovery could lead to faster diagnosis for some chronic fatigue syndrome cases

Date:
November 14, 2012
Source:
Ohio State University
Summary:
For the first time, researchers have landed on a potential diagnostic method to identify at least a subset of patients with chronic fatigue syndrome - testing for antibodies linked to latent Epstein-Barr virus reactivation.
Share:
FULL STORY

For the first time, researchers have landed on a potential diagnostic method to identify at least a subset of patients with chronic fatigue syndrome (CFS), a complex disorder with no known definitive cause or cure.

advertisement

In a pilot study of six patients, scientists detected specific antibodies linked to latent Epstein-Barr virus reactivation in blood samples from people who had experienced classic CFS symptoms and responded to antiviral treatment. Control blood samples from 20 healthy people showed no such antibodies.

The research team, led by scientists from Ohio State University and Oakland University William Beaumont School of Medicine, acknowledges that the number of patients is small. But the researchers say the study's power rests in their access to 16 months of blood samples for each patient -- a collection allowing for an unprecedented longitudinal look at CFS.

The researchers plan to move forward with development of a clinical laboratory test that can detect these antibodies in blood samples.

The study is published in the Nov. 14 issue of the journal PLOS ONE.

The Epstein-Barr virus is a human herpes virus that causes infectious mononucleosis and several different types of tumors. An estimated 95 percent of Americans have been infected with the virus by adulthood, according to the Centers for Disease Control and Prevention (CDC), but fewer than half have experienced an active illness. Once a person is infected, the virus remains dormant in the body, and can be reactivated without causing symptoms of illness.

advertisement

In these six patients, the study suggests that a latent Epstein-Barr virus had begun to reactivate, but that the newly awakened virus never reached its full potential to take over its host cells. That partial reactivation advanced enough to generate at least two viral proteins, DNA polymerase and dUTPase, and these patients produced antibodies specifically designed to identify and neutralize those proteins for more than a year.

The scientists theorize that even in the absence of a complete active infection, these viral proteins' ability to induce inflammatory chemical signals causes enough immune system chaos to lead to CFS. The disorder's main symptom is profound fatigue for at least six months that does not improve with rest, and is accompanied by problems that can include weakness, muscle pain, impaired memory and depression. Because the illness mimics many other disorders, diagnosis is difficult. An estimated 1 million Americans have CFS, but experts believe only 20 percent are diagnosed.

The study's senior researchers agree that the work should be repeated in more patients "to confirm that these observations are real," said virologist Ron Glaser, director of the Institute for Behavioral Medicine Research at Ohio State and a co-author of the study. "But finally, after more than 20 years, this is at least something to go on."

Glaser's primary collaborators on this work are Marshall Williams, professor of molecular virology, immunology and medical genetics at Ohio State, and A. Martin Lerner, a professor of internal medicine at Oakland University William Beaumont School of Medicine.

Ohio State and Lerner's private practice, CFS LLC, have applied for a patent for the diagnostic method.

advertisement

Glaser and Williams first published a paper in 1988 suggesting that these two viral proteins associated with partially reactivated Epstein-Barr virus could function as biomarkers for certain illnesses, including CFS. Meanwhile, Lerner became severely ill in 1986 and struggled for 10 years with CFS symptoms before treatment with antivirals dramatically improved his health.

Lerner, an infectious diseases specialist, runs his private CFS practice in Michigan, and his long-term tracking of patients' characteristics and response to treatment made this longitudinal research possible.

The fact that CFS patients experience different symptoms and multiple types of viral and bacterial infections has led researchers to believe CFS potentially has numerous causes. That lack of uniformity also complicates the diagnostic process and development of treatments.

"Part of the problem in trying to identify an agent or biomarkers for chronic fatigue syndrome is the extreme variability among people who say they have CFS. How to sort that out has held the field back a lot of years," said Glaser, who has studied the Epstein-Barr virus (EBV) for decades.

Lerner had long ago separated 142 of his patients into two groups: those who had tested positive for various antibodies against three types of herpes viruses and responded to months-long treatment with one of two types of antivirals, and a smaller group that had viral infections and a variety of co-infections who showed minimal response to antiviral treatment. As part of this tracking, he collected multiple blood serum samples for more than a year from each patient.

From those patients, he selected blood samples from six for this study. Five had been identified as an Epstein-Barr virus subset, and the sixth had Epstein-Barr virus and a bacterial co-infection. For comparison, researchers collected samples from 20 healthy people matched to the six CFS patients for age and sex.

Lerner, too, had independently hypothesized that CFS patients might be experiencing partial virus reactivation. Patients might test negative for the most active antibodies required to fight a virus, but could still recover from CFS after long-term antiviral treatment. One antiviral he uses is known to inhibit DNA polymerase, which would halt Epstein-Barr virus reactivation in its tracks.

With the CFS patients' and control blood samples in hand, Williams used a highly sensitive laboratory method to detect whether they contained antibodies to the two target Epstein-Barr viral proteins, DNA polymerase and dUTPase, that are produced early in the process of viral reactivation.

Overall, 78.8 percent of the serum samples from the six CFS patients were positive for antibodies against DNA polymerase and 44.2 percent were positive for antibodies against dUTPase. No antibodies to these two proteins were detected in the 20 control samples.

"Every one of the six had antibodies to DNA polymerase or EBV dUTPase and those antibodies persisted over some 408 days," Lerner said. "And the antibody levels were extraordinarily high." High levels of antibodies circulating in the blood suggest long-term immune activation against those proteins.

Williams noted that the levels might be less significant than the antibodies being present in the first place.

"If you look at most healthy individuals, they wouldn't have any reason to have an antibody against either of these proteins," he said. "The antibodies alone are a good differentiator."

This work was partially supported by the National Institutes of Health.

Additional co-authors include Maria Ariza of the Department of Molecular Virology, Immunology and Medical Genetics and Stanley Lemeshow, dean of the College of Public Health, both at Ohio State; Leonard Jason of DePaul University; Safedin Beqaj of Pathology Inc., in Torrance, Calif.; and James Fitzgerald of the University of Michigan School of Medicine.

make a difference: sponsored opportunity

Story Source:

Materials provided by Ohio State University. Original written by Emily Caldwell. Note: Content may be edited for style and length.


Journal Reference:

  1. A. Martin Lerner, Maria E. Ariza, Marshall Williams, Leonard Jason, Safedin Beqaj, James T. Fitzgerald, Stanley Lemeshow, Ronald Glaser. Antibody to Epstein-Barr Virus Deoxyuridine Triphosphate Nucleotidohydrolase and Deoxyribonucleotide Polymerase in a Chronic Fatigue Syndrome Subset. PLoS ONE, 2012; 7 (11): e47891 DOI: 10.1371/journal.pone.0047891

Cite This Page:

  • MLA
  • APA
  • Chicago
Ohio State University. "Discovery could lead to faster diagnosis for some chronic fatigue syndrome cases." ScienceDaily. ScienceDaily, 14 November 2012. <www.sciencedaily.com/releases/2012/11/121114171708.htm>.
Ohio State University. (2012, November 14). Discovery could lead to faster diagnosis for some chronic fatigue syndrome cases. ScienceDaily. Retrieved October 20, 2022 from www.sciencedaily.com/releases/2012/11/121114171708.htm
Ohio State University. "Discovery could lead to faster diagnosis for some chronic fatigue syndrome cases." ScienceDaily. www.sciencedaily.com/releases/2012/11/121114171708.htm (accessed October 20, 2022).

  • RELATED TOPICS
    • Health & Medicine
      • Chronic Fatigue Syndrome
      • Viruses
      • Today's Healthcare
      • Infectious Diseases
      • Diseases and Conditions
      • HIV and AIDS
      • Lymphoma
      • Patient Education and Counseling
advertisement

  • RELATED TERMS
    • Epstein-Barr virus
    • Chronic fatigue syndrome
    • Infectious mononucleosis
    • Obstructive sleep apnea
    • Hyperthyroidism
    • Delayed sleep phase syndrome
    • Rett syndrome
    • Biopharmaceutical
advertisement

  Print   Email   Share

advertisement

1

2

3

4

5
Most Popular
this week

HEALTH & MEDICINE
Eating Late Increases Hunger, Decreases Calories Burned, and Changes Fat Tissue
Clusters of Genes Help Mice Live Longer
Study of Over 5 Million People's DNA Reveals Genetic Links to Height
MIND & BRAIN
Dogs Can Smell When We're Stressed, Study Suggests
Human Brain Cells in a Dish Learn to Play Pong in Real Time
Healthy Aging Requires an Understanding of Personality Types
LIVING & WELL
Did the Pandemic Change Our Personalities?
Watching TV With Your Child Can Help Their Cognitive Development, Study Suggests
Coffee Drinking Is Associated With Increased Longevity
advertisement

Strange & Offbeat
 

HEALTH & MEDICINE
RNA Origami Enables Applications in Synthetic Biology
Unlocking the Power of Our Emotional Memory
Robotic Drug Capsule Can Deliver Drugs to Gut
MIND & BRAIN
Our Brains Use Quantum Computation
Human Brain Cells in a Dish Learn to Play Pong in Real Time
Dogs Can Smell When We're Stressed, Study Suggests
LIVING & WELL
Researchers Develop Painless Tattoos That Can Be Self-Administered
Washing Dishes With Superheated Steam More Effective, Earth-Friendly
News Addiction Linked to Not Only Poor Mental Wellbeing but Physical Health Too, New Study Shows
Explore More
from ScienceDaily

RELATED STORIES

SARS-CoV-2 Can Trigger Chronic Fatigue Syndrome, Study Finds
Aug. 31, 2022 — Since the beginning of the pandemic, SARS-CoV-2 has been suspected of causing chronic fatigue syndrome (ME/CFS). A well-controlled study has now shown that, even after mild COVID-19, a subset of ...
Novel Therapeutic Approach Against Epstein-Barr Virus-Associated Tumors
Oct. 11, 2020 — A research team hsd discovered that certain exosomes can effectively control Epstein-Barr virus-associated tumors and induce T-cell anti-tumor immunity. The novel findings provide insights into new ...
Key Protein for Epstein-Barr Virus Infection
Aug. 29, 2019 — Two studies reveal the portal structure of the Epstein-Barr virus and bacteriophage T7. No treatment is currently available for the infection caused by the Epstein-Barr virus, which, in addition to ...
Schizophrenia Linked With Abnormal Immune Response to Epstein-Barr Virus
Jan. 9, 2019 — New research shows that people in the study with schizophrenia also have higher levels of antibodies against the Epstein-Barr virus (EBV), a herpes virus that causes infectious mononucleosis, ...
advertisement


SD
  • SD
    • Home Page
    • Top Science News
    • Latest News
  • Home
    • Home Page
    • Top Science News
    • Latest News
  • Health
    • View all the latest top news in the health sciences,
      or browse the topics below:
      Health & Medicine
      • Allergy
      • Alternative Medicine
      • Birth Control
      • Cancer
      • Diabetes
      • Diseases
      • Heart Disease
      • HIV and AIDS
      • Obesity
      • Stem Cells
      • ... more topics
      Mind & Brain
      • ADD and ADHD
      • Addiction
      • Alzheimer's
      • Autism
      • Depression
      • Headaches
      • Intelligence
      • Psychology
      • Relationships
      • Schizophrenia
      • ... more topics
      Living Well
      • Parenting
      • Pregnancy
      • Sexual Health
      • Skin Care
      • Men's Health
      • Women's Health
      • Nutrition
      • Diet and Weight Loss
      • Fitness
      • Healthy Aging
      • ... more topics
  • Tech
    • View all the latest top news in the physical sciences & technology,
      or browse the topics below:
      Matter & Energy
      • Aviation
      • Chemistry
      • Electronics
      • Fossil Fuels
      • Nanotechnology
      • Physics
      • Quantum Physics
      • Solar Energy
      • Technology
      • Wind Energy
      • ... more topics
      Space & Time
      • Astronomy
      • Black Holes
      • Dark Matter
      • Extrasolar Planets
      • Mars
      • Moon
      • Solar System
      • Space Telescopes
      • Stars
      • Sun
      • ... more topics
      Computers & Math
      • Artificial Intelligence
      • Communications
      • Computer Science
      • Hacking
      • Mathematics
      • Quantum Computers
      • Robotics
      • Software
      • Video Games
      • Virtual Reality
      • ... more topics
  • Enviro
    • View all the latest top news in the environmental sciences,
      or browse the topics below:
      Plants & Animals
      • Agriculture and Food
      • Animals
      • Biology
      • Biotechnology
      • Endangered Animals
      • Extinction
      • Genetically Modified
      • Microbes and More
      • New Species
      • Zoology
      • ... more topics
      Earth & Climate
      • Climate
      • Earthquakes
      • Environment
      • Geography
      • Geology
      • Global Warming
      • Hurricanes
      • Ozone Holes
      • Pollution
      • Weather
      • ... more topics
      Fossils & Ruins
      • Ancient Civilizations
      • Anthropology
      • Archaeology
      • Dinosaurs
      • Early Humans
      • Early Mammals
      • Evolution
      • Lost Treasures
      • Origin of Life
      • Paleontology
      • ... more topics
  • Society
    • View all the latest top news in the social sciences & education,
      or browse the topics below:
      Science & Society
      • Arts & Culture
      • Consumerism
      • Economics
      • Political Science
      • Privacy Issues
      • Public Health
      • Racial Disparity
      • Religion
      • Sports
      • World Development
      • ... more topics
      Business & Industry
      • Biotechnology & Bioengineering
      • Computers & Internet
      • Energy & Resources
      • Engineering
      • Medical Technology
      • Pharmaceuticals
      • Transportation
      • ... more topics
      Education & Learning
      • Animal Learning & Intelligence
      • Creativity
      • Educational Psychology
      • Educational Technology
      • Infant & Preschool Learning
      • Learning Disorders
      • STEM Education
      • ... more topics
  • Quirky
    • Top News
    • Human Quirks
    • Odd Creatures
    • Bizarre Things
    • Weird World
Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

  • Email Newsletters
  • RSS Feeds
Follow Us

Keep up to date with the latest news from ScienceDaily via social networks:

  • Facebook
  • Twitter
  • LinkedIn
Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

  • Leave Feedback
  • Contact Us
About This Site  |  Staff  |  Reviews  |  Contribute  |  Advertise  |  Privacy Policy  |  Editorial Policy  |  Terms of Use
Copyright 1995-2022 ScienceDaily or by other parties, where indicated. All rights controlled by their respective owners.
Content on this website is for information only. It is not intended to provide medical or other professional advice.
Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its partners.
Financial support for ScienceDaily comes from advertisements and referral programs, where indicated.
— CCPA: Do Not Sell My Information — GDPR: Privacy Settings —